10 active not recruiting, 9 recruiting, 3 completed, 3 terminated. 13 Phase 2, 7 Phase 1, 2 Early Phase 1, 2 Not applicable, 1 Phase 3.
Follow Stage III Rectal Cancer AJCC v8: new trials by email Literature Review of Stage III Rectal Cancer AJCC v8 trials Research Report on Stage III Rectal Cancer AJCC v8
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Zanidatamab Before Surgery for the Treatment of HER2 Positive Colon and Rectal Cancer in Patients Planned for Curative Intent Treatment Zanidatamab, Resection, Patient Observation - Colon Carcinoma, Colorectal Carcinoma | Phase 2 | Recruiting | Emory University | 38 | 2026-04-07 | 2026-04-17 |
| Family Communications After Genetic Testing Biospecimen Collection, Genetic Testing, Communication Intervention - Colon Adenocarcinoma, Colorectal Adenocarcinoma | Not applicable | Recruiting | Alliance for Clinical Trials in Oncology | 4186 | 2026-04-06 | 2026-10-02 |
| FOLFOX, Botensilimab, and Balstilimab for the Treatment of Localized Rectal Cancer Before Surgery Balstilimab, Biospecimen Collection, Botensilimab - Rectal Adenocarcinoma, Stage IIA Rectal Cancer AJCC v8 | Phase 2 | Recruiting | City of Hope Medical Center | 26 | 2025-05-20 | 2026-06-29 |
| Papaverine in Combination With Radiation Therapy for the Treatment of Locally Advanced Rectal Cancer, DINOMITE Trial Biospecimen Collection, Computed Tomography, Consolidation Therapy - Locally Advanced Rectal Adenocarcinoma, Stage II Rectal Cancer AJCC v8 | Phase 1 | Recruiting | City of Hope Medical Center | 36 | 2025-04-07 | 2026-07-22 |
| Botensilimab, Balstilimab and Regorafenib or Botensilimab and Balstilimab for the Treatment of Advanced or Metastatic Microsatellite Stable Colorectal Cancer Balstilimab, Biopsy, Biospecimen Collection - Advanced Colon Adenocarcinoma, Advanced Colorectal Adenocarcinoma | Phase 2 | Withdrawn | City of Hope Medical Center | 2024-11-01 | 2024-11-21 | |
| Designing a Dyad-Based mHealth Intervention to Improve Adherence to Lifestyle Recommendations in Colorectal Cancer Survivors and Their Family Caregivers Discussion, Educational Activity, Internet-Based Intervention - Stage I Colon Cancer AJCC v8, Stage I Rectal Cancer AJCC v8 | Not applicable | Recruiting | Ohio State University Comprehensive Cancer Center | 70 | 2024-05-03 | 2026-04-09 |
| Active Surveillance and Chemotherapy Before Surgery in Treating Participants With Stage II-III Rectal Cancer Chemotherapy, Patient Observation, Questionnaire Administration - Rectal Adenocarcinoma, Stage II Rectal Cancer AJCC v8 | Early Phase 1 | Recruiting | M.D. Anderson Cancer Center | 120 | 2024-03-13 | 2026-05-20 |
| Time-Restricted Eating Versus Nutritional Counseling for the Reduction of Radiation or Chemoradiation Tx Side Effects in Patients With Prostate, Cervical, or Rectal Cancers Biospecimen Collection, Informational Intervention, Quality-of-Life Assessment - Localized Prostate Carcinoma, Locally Advanced Cervical Carcinoma | Phase 2 | Active not recruiting | City of Hope Medical Center | 49 | 2023-03-23 | 2026-10-20 |
| Testing the Addition of an Anti-Cancer Drug, Irinotecan, to the Standard Chemotherapy Treatment (FOLFOX) After Long-Course Radiation Therapy for Advanced-Stage Rectal Cancers to Improve the Rate of Complete Response and Long-Term Rates of Organ Preservation and Continuing Response Capecitabine, 5-fluorouracil, Leucovorin calcium - Stage II Rectal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8 | Phase 2 / Phase 3 | Active not recruiting | Alliance for Clinical Trials in Oncology | 760 | 2022-12-08 | 2026-09-25 |
| An Investigational Scan (64Cu-Labeled M5A Antibody) in Combination With SOC Chemotherapy and Radiotherapy in Locally Advanced Rectal Cancer Copper Cu 64 Anti-CEA Monoclonal Antibody M5A, Imaging Technique - Locally Advanced Rectal Carcinoma, Stage III Rectal Cancer AJCC v8 | Early Phase 1 | Active not recruiting | City of Hope Medical Center | 14 | 2022-08-31 | 2026-06-08 |
| Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer Anoscopy, Biospecimen Collection, Capecitabine - AIDS-Related Anal Carcinoma, Anal Margin Squamous Cell Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 40 | 2022-08-09 | 2026-10-05 |
| Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation Cetuximab, Encorafenib, Nivolumab - Metastatic Colon Adenocarcinoma, Metastatic Rectal Adenocarcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 86 | 2022-07-19 | 2026-07-08 |
| Testing Nivolumab and Ipilimumab With Short-Course Radiation in Locally Advanced Rectal Cancer Computed Tomography, Ipilimumab, Magnetic Resonance Imaging - Locally Advanced Rectal Adenocarcinoma, Stage II Rectal Cancer AJCC v8 | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 31 | 2022-02-08 | 2026-10-22 |
| Establishing a ctDNA Biomarker to Improve Organ Preserving Strategies in Patients With Rectal Cancer Biopsy, Biospecimen Collection, Electronic Health Record Review - Rectal Adenocarcinoma, Stage II Rectal Cancer AJCC v8 | Recruiting | OHSU Knight Cancer Institute | 50 | 2021-09-03 | 2026-09-16 | |
| Testing the Addition of a Radiation Sensitizing Drug, IPdR, to the Usual Chemotherapy Treatment (Capecitabine) During Radiation Therapy for Rectal Cancer Capecitabine, Radiation Therapy, Ropidoxuridine - Locally Advanced Rectal Carcinoma, Rectal Adenocarcinoma | Phase 1 | Terminated | National Cancer Institute (NCI) | 1 | 2021-03-17 | 2025-02-26 |
| Short Course Radiation Therapy and Combination Chemotherapy for the Treatment of Stage II-III Rectal Cancer Capecitabine, Fluorouracil, Intensity-Modulated Radiation Therapy - Locally Advanced Rectal Carcinoma, Rectal Adenocarcinoma | Phase 1 | Recruiting | Jonsson Comprehensive Cancer Center | 25 | 2021-02-11 | 2026-03-30 |
| LY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastatic Colorectal Cancer Abemaciclib, Cetuximab, ERK1/2 Inhibitor LY3214996 - Metastatic Colon Adenocarcinoma, Metastatic Colorectal Carcinoma | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 46 | 2020-12-02 | 2026-10-05 |
| SX-682 and Nivolumab for the Treatment of RAS-Mutated, MSS Unresectable or Metastatic Colorectal Cancer, the STOPTRAFFIC-1 Trial CXCR1/2 Inhibitor SX-682, Nivolumab - Metastatic Colon Adenocarcinoma, Metastatic Colorectal Carcinoma | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 51 | 2020-10-14 | 2026-07-20 |
| Regorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal Cancer Ipilimumab, Nivolumab, Regorafenib - Advanced Colon Adenocarcinoma, Metastatic Colon Adenocarcinoma | Phase 1 | Completed | City of Hope Medical Center | 39 | 2020-05-27 | 2026-01-28 |
| Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer Panitumumab, Quality-of-Life Assessment, Questionnaire Administration - Metastatic Colon Adenocarcinoma, Metastatic Colorectal Carcinoma | Phase 2 | Unknown | Academic and Community Cancer Research United | 12 | 2020-04-24 | 2024-05-21 |
Showing 20 of 27. Sign in to see all of them.
Rectal Neoplasms (27) · Colonic Neoplasms (13) · Colorectal Neoplasms (9) · Anus Neoplasms (1) · HIV Infections (1) · Prostatic Neoplasms (1)
Digestive System Diseases (27) · Digestive System Neoplasms (27) · Gastrointestinal Diseases (27) · Gastrointestinal Neoplasms (27) · Intestinal Diseases (27) · Intestinal Neoplasms (27) · Neoplasms (27) · Neoplasms by Site (27) · Rectal Diseases (27) · Colorectal Neoplasms (18) · Colonic Diseases (13) · Genital Diseases (2) · Urogenital Diseases (2) · Anus Diseases (1) · Blood-Borne Infections (1)
Magnetic Resonance Spectroscopy (7) · Specimen Handling (6) · Biopsy (5) · Capecitabine (5) · Nivolumab (5) · Fluorouracil (4) · Radiation (4) · Radiotherapy (4) · Sigmoidoscopy (4) · Leucovorin (3) · Oxaliplatin (3) · Radiotherapy, Intensity-Modulated (3) · Trifluridine (3) · dehydroftorafur (3) · regorafenib (3)
City of Hope Medical Center (6) · M.D. Anderson Cancer Center (5) · National Cancer Institute (NCI) (5) · Academic and Community Cancer Research United (2) · Alliance for Clinical Trials in Oncology (2) · OHSU Knight Cancer Institute (2) · ECOG-ACRIN Cancer Research Group (1) · Emory University (1) · Jonsson Comprehensive Cancer Center (1) · Ohio State University Comprehensive Cancer Center (1) · Roswell Park Cancer Institute (1)
United States (26) · Puerto Rico (3)
John H Strickler (3) · Marwan G Fakih (2) · Adel Kardosh, M.D.,Ph.D. (1) · Alisha Bent, MD (1) · Ann Raldow (1) · Charles D Lopez, MD, PhD (1) · Charles Kunos (1) · Christine M Parseghian, MD (1) · Christos Fountzilas, MD (1) · Frank A Sinicrope (1) · George Chang (1) · George J Chang (1) · J. Joshua Smith, MD (1) · Jeffrey Y Wong (1) · Kristen K Ciombor (1)
PMID 36892833, PMID 37369852, PMID 37647138, PMID 38194233, PMID 38712176, PMID 39060961, PMID 39116386, PMID 39244627, PMID 39287948, PMID 39652198, PMID 41781240, PMID 42328901
P30CA033572 (5), P30CA015083 (2), U10CA180820 (2), K07CA133187 (1), P30CA138292 (1), R01CA187238 (1), R01CA297752 (1), U10CA180821 (1), U10CA180888 (1), UG1CA189828 (1), UM1CA121947 (1), UM1CA186644 (1), UM1CA186704 (1), UM1CA186712 (1), UM1CA186716 (1)